True Wealth Design’s Bicara Therapeutics BCAX Stock Holding History

True Wealth Design’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$429	Hold	23	–	–	﹤0.01%	2175
2026 Q2	$683	Hold	23	–	–	﹤0.01%	2101
2026 Q1	$458	Hold	23	–	–	﹤0.01%	2089
2025 Q4	$388	Hold	23	–	–	﹤0.01%	2030
2025 Q3	$364	Hold	23	–	–	﹤0.01%	2110
2025 Q2	$214	Sell	23 -10	-30%	-$119	﹤0.01%	2053
2025 Q1	$430	Buy	+33	New	+$438	﹤0.01%	1605

Other funds holding BCAX

RTM

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

True Wealth Design's BCAX Position: Q3 2026 in Review

True Wealth Design held its Bicara Therapeutics (BCAX) position steady in Q3 2026 at 23 shares worth $429. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

True Wealth Design first reported a position in BCAX in Q1 2025 and has held it in 7 quarters since. The position peaked at $683 in Q2 2026. 9 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

True Wealth Design held 23 shares of Bicara Therapeutics worth $429 as of Q3 2026.
True Wealth Design left its Bicara Therapeutics share count unchanged in Q3 2026.
Bicara Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2175 holding.
True Wealth Design first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 7 quarters since.
True Wealth Design's Bicara Therapeutics position peaked at $683 in Q2 2026.
9 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.